» Articles » PMID: 35455363

Surviving the Storm: Cytokine Biosignature in SARS-CoV-2 Severity Prediction

Overview
Date 2022 Apr 23
PMID 35455363
Authors
Affiliations
Soon will be listed here.
Abstract

A significant part of the world population has been affected by the devastating SARS-CoV-2 infection. It has deleterious effects on mental and physical health and global economic conditions. Evidence suggests that the pathogenesis of SARS-CoV-2 infection may result in immunopathology such as neutrophilia, lymphopenia, decreased response of type I interferon, monocyte, and macrophage dysregulation. Even though most individuals infected with the SARS-CoV-2 virus suffer mild symptoms similar to flu, severe illness develops in some cases, including dysfunction of multiple organs. Excessive production of different inflammatory cytokines leads to a cytokine storm in COVID-19 infection. The large quantities of inflammatory cytokines trigger several inflammation pathways through tissue cell and immune cell receptors. Such mechanisms eventually lead to complications such as acute respiratory distress syndrome, intravascular coagulation, capillary leak syndrome, failure of multiple organs, and, in severe cases, death. Thus, to devise an effective management plan for SARS-CoV-2 infection, it is necessary to comprehend the start and pathways of signaling for the SARS-CoV-2 infection-induced cytokine storm. This article discusses the current findings of SARS-CoV-2 related to immunopathology, the different paths of signaling and other cytokines that result in a cytokine storm, and biomarkers that can act as early signs of warning for severe illness. A detailed understanding of the cytokine storm may aid in the development of effective means for controlling the disease's immunopathology. In addition, noting the biomarkers and pathophysiology of severe SARS-CoV-2 infection as early warning signs can help prevent severe complications.

Citing Articles

Paradoxical Immune Reconstitution Inflammatory Syndrome in SARS-CoV-2 Infection After Improvement of Chemotherapy-Induced Aplasia.

Canelas Mendes C, Howell Monteiro P, Madeira Lopes J, Pais de Lacerda A Cureus. 2023; 15(10):e46723.

PMID: 38022239 PMC: 10631116. DOI: 10.7759/cureus.46723.


The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial.

Hammersen J, Birndt S, Dohner K, Reuken P, Stallmach A, Sauerbrey P Leukemia. 2023; 37(9):1879-1886.

PMID: 37507425 PMC: 10457200. DOI: 10.1038/s41375-023-01979-w.


Evaluation of Remdesivir Utilization Pattern in Critically Ill Patients With COVID-19 in Jazan Province.

Ayyashi M, Darbashi H, Hakami A, Sharahili F Cureus. 2023; 15(3):e36247.

PMID: 37069861 PMC: 10105617. DOI: 10.7759/cureus.36247.


Association of SARS-CoV-2 nucleocapsid viral antigen and the receptor for advanced glycation end products with development of severe disease in patients presenting to the emergency department with COVID-19.

Matthay Z, Fields A, Wick K, Jones C, Lane H, Herrera K Front Immunol. 2023; 14:1130821.

PMID: 37026003 PMC: 10070743. DOI: 10.3389/fimmu.2023.1130821.


Clinical Investigation of Leukocyte DNA Damage in COVID-19 Patients.

Dogan H, Kara A, Cankaya E, Balkan E, Gurbuz M, Kizilkaya M Curr Issues Mol Biol. 2023; 45(2):963-974.

PMID: 36826007 PMC: 9955698. DOI: 10.3390/cimb45020062.


References
1.
Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y . Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. Clin Infect Dis. 2020; 71(16):2027-2034. PMC: 7184337. DOI: 10.1093/cid/ciaa344. View

2.
Al-Samkari H, Berliner N . Hemophagocytic Lymphohistiocytosis. Annu Rev Pathol. 2017; 13:27-49. DOI: 10.1146/annurev-pathol-020117-043625. View

3.
Rosenberg S . IL-2: the first effective immunotherapy for human cancer. J Immunol. 2014; 192(12):5451-8. PMC: 6293462. DOI: 10.4049/jimmunol.1490019. View

4.
Li X, Liu H, Meng Y, Yin H, Gao W, Yang X . Critical roles of cytokine storm and secondary bacterial infection in acute kidney injury development in COVID-19: A multi-center retrospective cohort study. J Med Virol. 2021; 93(12):6641-6652. PMC: 8426723. DOI: 10.1002/jmv.27234. View

5.
Siddiqi Z, Fatima J, Bhatt D, Shukla V, Malik M, Ashfaq A . Prevalence of Comorbidities in Survivors and Non-Survivors of Severe COVID-19 at a Dedicated COVID Care Centre. J Assoc Physicians India. 2022; 70(1):11-12. View